Journal
SCIENTIFIC REPORTS
Volume 12, Issue 1, Pages -Publisher
NATURE PORTFOLIO
DOI: 10.1038/s41598-022-24730-4
Keywords
-
Categories
Funding
- Japan Society for the Promotion of Science (JSPS) [21K08503, 22H02557, 22K07850, JP20K22630, JP25000013]
- Japan Agency for Medical Research and Development (AMED) [21fk0108467h0001, 22ek0109579s0101]
- Platform Project for Supporting Drug Discovery and Life Science Research (BINDS) from AMED [JP21am0101117]
- Cyclic Innovation for Clinical Empowerment (CiCLE) from AMED [JP17pc0101020]
- JEOL YOKOGUSHI Research Alliance Laboratory of Osaka University
- Japan Science and Technology Agency (JST) Moonshot RD [JPMJMS2025]
- Ministry of Health, Labour and Welfare (MHLW) Grant [19HA1003]
Ask authors/readers for more resources
This study investigated neutralizing antibodies against new variants of the coronavirus and identified two antibodies that were able to neutralize the wild-type virus and the Delta variant, but not the Omicron variant. One of the antibodies targeted the N-terminal domain of the S1 subunit and inhibited S1/S2 cleavage, thus preventing viral entry. The results suggest that neutralizing antibodies targeting S1/S2 cleavage inhibition may have cross-reactivity against multiple virus variants.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19). Variants of concern (VOCs) such as Delta and Omicron have developed, which continue to spread the pandemic. It has been reported that these VOCs reduce vaccine efficacy and evade many neutralizing monoclonal antibodies (mAbs) that target the receptor binding domain (RBD) of the glycosylated spike (S) protein, which consists of the S1 and S2 subunits. Therefore, identification of optimal target regions is required to obtain neutralizing antibodies that can counter VOCs. Such regions have not been identified to date. We obtained 2 mAbs, NIBIC-71 and 7G7, using peripheral blood mononuclear cells derived from volunteers who recovered from COVID-19. Both mAbs had neutralizing activity against wild-type SARS-CoV-2 and Delta, but not Omicron. NIBIC-71 binds to the RBD, whereas 7G7 recognizes the N-terminal domain of the S1. In particular, 7G7 inhibited S1/S2 cleavage but not the interaction between the S protein and angiotensin-converting enzyme 2; it suppressed viral entry. Thus, the efficacy of a neutralizing mAb targeting inhibition of S1/2 cleavage was demonstrated. These results suggest that neutralizing mAbs targeting blockade of S1/S2 cleavage are likely to be cross-reactive against various VOCs.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available